AAD 2019—Hair loss: a potential for platelet-rich plasma therapy


  • Marielle Fares, Pharm.D.
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A prospective randomized trial indicated that treatment of androgenic alopecia (AGA) with platelet-rich plasma (PRP) products is safe and effective among both men and women

Why this matters

  • Previous clinical studies have pointed to the safety and effectiveness of PRP in the treatment of AGA.

Key results

  • At 6 months, both patient groups studied had a statistically significant increase in hair count (P<.001 and a higher more rapid response was seen in group>
  • Patients in group 1 received 3 subdermal PRP injections per month and a booster dose after 3 months.
  • Patients in group 2 received 2 subdermal PRP injections every 3 months.
  • Folliscope hair count increased significantly (29.6±13.6 in group 1 vs 7.2±10.4 in group 2; P<.001 in both groups.>
  • Shaft caliber increased significantly in both groups with no significant difference between groups.
  • Survey results showed patients had high satisfaction with treatment (82% of patients were satisfied or highly satisfied).
  • Treatment was well-tolerated, with a mean pain score of 2.1.

Study design

  • 40 patients with moderate AGA were analyzed in a prospective randomized single-blinded trial.
  • Patients were randomly assigned according to 2 treatment protocols (group 1 received 3 injections per month followed by a booster dose at 3 months, and group 2 received 2 injections every 3 months).
  • Funding: Eclipse Aesthetics, LLC.

Limitations

  • Small number of patients.